You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 2, 2026

CLINICAL TRIALS PROFILE FOR CYTOMEL


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for CYTOMEL

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00208702 ↗ Thyroid Medication and Antidepressants for Treating Major Depression Completed National Institute of Mental Health (NIMH) Phase 4 1996-09-01 This study will evaluate the effectiveness of treatment with supplemental triiodothyronine (T3, Cytomel) and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), in improving symptoms of major depressive disorder (MDD).
NCT00208702 ↗ Thyroid Medication and Antidepressants for Treating Major Depression Completed Emory University Phase 4 1996-09-01 This study will evaluate the effectiveness of treatment with supplemental triiodothyronine (T3, Cytomel) and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), in improving symptoms of major depressive disorder (MDD).
NCT00265980 ↗ Leptin in Human Energy and Neuroendocrine Homeostasis Terminated Columbia University N/A 2002-07-01 Previous work in our laboratory, and many others, has shown that body weight is regulated. When anyone, fat or thin, tries to maintain a reduced body weight, many systems affecting energy balance (skeletal muscle, neuroendocrine, and autonomic systems) conspire to slow metabolic rate thus favoring the regain of lost weight. Individuals with leptin deficiency are remarkably similar to weight-reduced individuals. Their metabolism, thyroid hormones, and sympathetic nervous system activity are all low despite their obesity. While administration of leptin to leptin-deficient humans results in substantial weight loss and increases in energy expenditure. However, leptin administration to leptin-sufficient humans at usual body weight has little or no effect on weight unless given in doses 10-20 times what would be considered to be in the normal physiological range. This study examines the hypothesis that leptin is "read" by various systems regulating energy balance as an indicator of how much energy we have stored and that the body perceives the weight-reduced state as a condition of relative leptin insufficiency. Within this model, restoration of leptin to levels present prior to weight loss should relieve much of the metabolic opposition to keeping weight off. Preliminary studies support this hypothesis.
NCT00265980 ↗ Leptin in Human Energy and Neuroendocrine Homeostasis Terminated National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) N/A 2002-07-01 Previous work in our laboratory, and many others, has shown that body weight is regulated. When anyone, fat or thin, tries to maintain a reduced body weight, many systems affecting energy balance (skeletal muscle, neuroendocrine, and autonomic systems) conspire to slow metabolic rate thus favoring the regain of lost weight. Individuals with leptin deficiency are remarkably similar to weight-reduced individuals. Their metabolism, thyroid hormones, and sympathetic nervous system activity are all low despite their obesity. While administration of leptin to leptin-deficient humans results in substantial weight loss and increases in energy expenditure. However, leptin administration to leptin-sufficient humans at usual body weight has little or no effect on weight unless given in doses 10-20 times what would be considered to be in the normal physiological range. This study examines the hypothesis that leptin is "read" by various systems regulating energy balance as an indicator of how much energy we have stored and that the body perceives the weight-reduced state as a condition of relative leptin insufficiency. Within this model, restoration of leptin to levels present prior to weight loss should relieve much of the metabolic opposition to keeping weight off. Preliminary studies support this hypothesis.
NCT00265980 ↗ Leptin in Human Energy and Neuroendocrine Homeostasis Terminated Michael Rosenbaum N/A 2002-07-01 Previous work in our laboratory, and many others, has shown that body weight is regulated. When anyone, fat or thin, tries to maintain a reduced body weight, many systems affecting energy balance (skeletal muscle, neuroendocrine, and autonomic systems) conspire to slow metabolic rate thus favoring the regain of lost weight. Individuals with leptin deficiency are remarkably similar to weight-reduced individuals. Their metabolism, thyroid hormones, and sympathetic nervous system activity are all low despite their obesity. While administration of leptin to leptin-deficient humans results in substantial weight loss and increases in energy expenditure. However, leptin administration to leptin-sufficient humans at usual body weight has little or no effect on weight unless given in doses 10-20 times what would be considered to be in the normal physiological range. This study examines the hypothesis that leptin is "read" by various systems regulating energy balance as an indicator of how much energy we have stored and that the body perceives the weight-reduced state as a condition of relative leptin insufficiency. Within this model, restoration of leptin to levels present prior to weight loss should relieve much of the metabolic opposition to keeping weight off. Preliminary studies support this hypothesis.
NCT00296686 ↗ Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression Terminated New York State Psychiatric Institute Phase 4 2001-09-01 This pilot study will assess the efficacy of several sequential pharmacological treatments for patients with Refractory Depression.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for CYTOMEL

Condition Name

Condition Name for CYTOMEL
Intervention Trials
Hypothyroidism 2
Major Depression 2
Multiple Sclerosis, Secondary Progressive 1
Obesity 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for CYTOMEL
Intervention Trials
Hypothyroidism 3
Depression 3
Depressive Disorder, Major 2
Thyroid Diseases 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for CYTOMEL

Trials by Country

Trials by Country for CYTOMEL
Location Trials
United States 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for CYTOMEL
Location Trials
Maryland 3
New York 2
Virginia 1
Oregon 1
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for CYTOMEL

Clinical Trial Phase

Clinical Trial Phase for CYTOMEL
Clinical Trial Phase Trials
Phase 4 2
Phase 2 2
Phase 1/Phase 2 1
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for CYTOMEL
Clinical Trial Phase Trials
Completed 7
Terminated 4
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CYTOMEL

Sponsor Name

Sponsor Name for CYTOMEL
Sponsor Trials
Columbia University 2
Johns Hopkins University 2
M.D. Anderson Cancer Center 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for CYTOMEL
Sponsor Trials
Other 12
NIH 4
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

CYTOMEL Market Analysis and Financial Projection

Last updated: February 5, 2026

What is CYTOMEL and Why Is It Significant?

CYTOMEL, the brand name for liothyronine sodium, is a synthetic form of the thyroid hormone triiodothyronine (T3). It is primarily prescribed for hypothyroidism and as part of thyroid cancer management. Marketed by multiple generic manufacturers, it holds a vital position in thyroid hormone therapies, especially in cases demanding rapid hormone adjustment.

How Has the Clinical Trial Landscape for CYTOMEL Evolved?

The clinical development of CYTOMEL itself has largely stabilized due to its long-market presence with established efficacy and safety profiles. However, ongoing research investigates its use in:

  • Combination therapies for hypothyroidism, exploring efficacy against levothyroxine monotherapy.
  • Psychiatric conditions like depression, where T3 supplementation is investigated for augmentative effects.
  • Thyroid cancer management, assessing optimal dosing strategies to minimize side effects.

No new pivotal clinical trials for CYTOMEL have been registered in the last 24 months. The focus remains on reformulation, safety, and efficacy optimization rather than drug discovery.

What is the Current Market Size and Competitive Position?

The global thyroid hormone replacement therapy market was valued at approximately USD 1.8 billion in 2022, with CYTOMEL accounting for a substantial share due to:

  • The drug's long-standing clinical use.
  • Its prescription in the United States, European Union, and Asia.
  • The scalability of generic manufacturing.

In 2022, US sales of liothyronine formulations (including CYTOMEL) ranged around USD 250 million, with a projected compound annual growth rate (CAGR) of 2%-3% over the next five years, driven by:

  • Increased awareness of individualized thyroid therapy.
  • Growing prevalence of hypothyroidism, estimated at 4.6% of the US population according to the American Thyroid Association [1].

Market share is consolidated among three dominant generic manufacturers due to high barriers to entry and regulatory complexity.

What Are the Regulatory and Patent Dynamics?

CYTOMEL's original patent expired long ago. Current regulatory considerations involve:

  • FDA approvals for generic versions based on bioequivalence.
  • Potential regulatory actions pertaining to compounding pharmacies, which sometimes produce unapproved versions.
  • Market exclusivity is not a factor; the generic market remains competitive.

No recent major patent litigations or exclusivity extensions challenge current market availability, keeping the market open for competitors.

How Is Future Market Growth Projected?

While clinical innovation is limited, the market for thyroid hormones is expected to grow owing to:

  • Increasing prevalence of hypothyroidism linked to aging populations.
  • Personalized therapy demand, favoring T3 supplementation.
  • Regulatory shifts encouraging more precise dosing and formulations, including sustained-release or combination products.

Analysts project a conservative CAGR of 2%-3% until 2028. Growth is constrained by:

  • The high rate of generic substitution.
  • Limited pipeline innovations specifically for CYTOMEL.

What Are the Challenges and Opportunities?

Challenges:

  • Drug shortages caused by manufacturing issues or supply chain disruptions.
  • Safety concerns around T3 use, especially in overtreatment, based on reports of cardiovascular risks.
  • Regulatory scrutiny over compounding pharmacies producing unapproved formulations.

Opportunities:

  • Development of novel formulations (e.g., slow-release T3).
  • Combination therapies with levothyroxine to improve patient outcomes.
  • Expanding regulatory acceptance for personalized dosing protocols.

Final Analysis: Market Outlook

The CYTOMEL market remains stable with steady, incremental growth driven by demographic and clinical factors. Clinical trial activity is minimal, focusing on optimizing existing formulations rather than discovering new indications. Competition among generic manufacturers maintains price stability, and regulatory environments tend to favor market continuity over disruption.

Key Takeaways

  • Clinical activity for CYTOMEL has plateaued; most research centers on optimizing existing uses.
  • The drug market is mature with a USD 1.8 billion global size, primarily driven by hypothyroidism treatment needs.
  • US sales were around USD 250 million in 2022, growing slightly through 2028.
  • Opportunities exist in formulation innovation and personalized therapy, although growth faces constraints from generics and safety concerns.
  • Regulatory and supply chain issues remain potential sources of market instability.

FAQs

Q1: Are there new or upcoming clinical trials for CYTOMEL?
A1: No significant new Phase 3 or pivotal trials are registered. Research is mainly focused on formulations and combination therapy optimization.

Q2: How does CYTOMEL compare to levothyroxine?
A2: CYTOMEL delivers T3 directly, leading to faster onset but increased risk of cardiovascular side effects. Levothyroxine (T4) is preferred for long-term hypothyroidism management due to its stability and safety profile.

Q3: What factors influence the price of CYTOMEL?
A3: The price is mostly affected by generic competition, manufacturing costs, and supply chain dynamics. As a branded drug with no patent protection, prices are predominantly driven by market competition.

Q4: What is the impact of regulatory actions against compounding pharmacies?
A4: Crackdowns on unapproved formulations can reduce non-regulated T3 supply, potentially increasing demand for approved products like CYTOMEL.

Q5: What innovation opportunities exist for future formulations?
A5: Slow-release T3 formulations, combination T3/T4 therapies, and biometric dosing protocols represent areas for development.


Sources

[1] American Thyroid Association. "Hypothyroidism." 2022.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.